An Open-label, Phase 1 Trial for Safety Study of HLA-haplo Matched Allogenic Bone Marrow Derived Stem Cell("HYNR-CS-Allo Inj") Treatment in Amyotrophic Lateral Sclerosis(ALS)
Phase of Trial: Phase I
Latest Information Update: 20 May 2019
Price : $35 *
At a glance
- Drugs HYNRCS-Allo-Corestem (Primary)
- Indications Amyotrophic lateral sclerosis
- Focus Adverse reactions
- 15 May 2019 Status changed from active, no longer recruiting to completed.
- 21 Feb 2018 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 17 Jul 2017 New trial record